Chimeric Antigen Receptor-T (CAR-T) therapies are just the beginning of the advancements in cellular therapy for patients who have failed other cancer treatments. Simply stated, the CAR-T therapy process is this: White blood cells are taken from the patient and genetically engineered to stimulate the body’s own defenses to recognize and attack the cancer cells. These engineered cells are multiplied and returned to the patient’s body along with chemotherapy to seek and destroy the targeted cancer cells. The Food and Drug Administration (FDA) approved two CAR-T therapies, Kymriah (tisagenlecleucel: Novartis) and Yescarta (axicabtagene ciloleucel or axi-cel: Gilead/Kite). The number of Kymriah and Yescarta approved treatment facilities is expanding rapidly. The costs of the drugs are $373,000 for Yescarta and Kymriah for treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and $475,000 for Kymriah for treatment of patients less than 25 years old with R/R acute lymphoblastic leukemia (ALL). In addition to the actual drugs, apheresis, hospitalization, and other nondrug costs add to the overall expense of this treatment.
Let LifeTrac make difficult easier.
Our Cellular Therapies Trac provides access to this cutting-edge CAR-T therapy to treat B-cell acute lymphoblastic leukemia and adult relapsed or refractory (R/R) large B-cell lymphoma. Cellular therapy requires a highly individualized regimen. LifeTrac is able to help you assess your member’s specific needs and negotiate significant discounts with the treatment center for your member’s care. CAR-T therapy is just one of several cellular therapies being developed, and LifeTrac will be expanding its product offering as new therapies become available.